Results 161 to 170 of about 924 (199)
Some of the next articles are maybe not open access.

Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex

Expert Review of Anti-Infective Therapy
Infections with Acinetobacter baumannii-calcoaceticus complex (ABC) pose difficulty for clinicians given a limited arsenal of effective antimicrobials. Sulbactam/durlobactam provides a novel treatment option for patients experiencing hospital- or ventilator-acquired pneumonia with susceptible strains.This review provides a comprehensive discussion of ...
Jordan R Covvey, Anthony J Guarascio
exaly   +3 more sources

Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections

Annals of Pharmacotherapy, 2023
Objective: To review the pharmacology, efficacy, and safety of intravenous sulbactam-durlobactam (SUL-DUR) in the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Data Sources: PubMed databases and ClinicalTrials.gov were searched using the following terms: Sulbactam Durlobactam, ETX2514, Xacduro, Sulbactam-ETX2514 ...
Benjamin August   +2 more
openaire   +2 more sources

Sulbactam/Durlobactam: First Approval

Drugs, 2023
Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC). Coadministration of durlobactam (a β-lactamase inhibitor with potent activity against a broad range of serine β-lactamases) with ...
openaire   +2 more sources

Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia

The Medical Letter on Drugs and Therapeutics, 2023
The FDA has approved Xacduro (Innoviva), a combination of the beta-lactam antibacterial sulbactam and the beta-lactamase inhibitor durlobactam, for IV treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC).
openaire   +2 more sources

Home - About - Disclaimer - Privacy